Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769352 · ClinicalTrials.gov registry record · Phase 2
Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)
A Phase 2 study of Post-surgical Cystoid Macular Edema (PSCME), sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT01769352 is a Phase 2 study of Post-surgical Cystoid Macular Edema (PSCME) that has completed, run by Johns Hopkins University. The registered enrollment target is 42 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01769352, a Phase 2 study of Post-surgical Cystoid Macular Edema (PSCME), has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the change in visual acuity of patients with post surgical cystoid macular edema who will be treated with two different regimens.
Conditions Studied
Interventions
- DRUG PredA + Kelac
Study Locations (1)
Maryland
- Wilmer Eye Institute - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01769352
The ClinicalTrials.gov registry entry for NCT01769352 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post-surgical Cystoid Macular Edema (PSCME) appearing as the primary indexed condition, and to 1 intervention - of which PredA + Kelac is the first listed.
NCT01769352 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01769352 about?
NCT01769352 is a clinical study titled "Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)". The purpose of this study is to compare the change in visual acuity of patients with post surgical cystoid macular edema who will be treated with two different regimens.
What is the current status of trial NCT01769352?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2012-08. Estimated completion is 2016-04.
What conditions does trial NCT01769352 study?
This clinical trial studies the following conditions: Post-surgical Cystoid Macular Edema (PSCME).
What interventions are being tested in trial NCT01769352?
The interventions under investigation include: PredA + Kelac (DRUG).
Who is sponsoring clinical trial NCT01769352?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01769352 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.